ArticlePloS one2025
Decoding oncogenic secrets of regulator of chromosome condensation 1: A breakthrough mechanistic evidence from breast and lung cancer models.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Berberine shows potential in mitigating PMApoptosis : an international journal on programmed cell death · 2026Article
- Article
- Article
- Efficacy, Safety and Predictive Biomarkers of Oncolytic Virus Therapy in Solid Tumors: A Systematic Review and Meta-Analysis.Vaccines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Regulator of Chromosome Condensation 1 (RCC1), a master regulator of cell cycle progression, chromatin structure, and nuclear transport, emerges as a powerful driver of cancer progression. Elevated RCC1 expression in breast and lung cancers is closely tied to enhanced tumor cell survival, proliferation, and metastasis, positioning it as a promising therapeutic target. This study unveils RCC1's pivotal role in cancer biology by silencing its expression in MDA-MB-231 (breast cancer) and A549 (lung cancer) cell lines using shRNA. RCC1 knockdown dramatically reduced cell viability, colony formation, and motility, while inducing apoptosis, as evidenced by increased apoptotic markers and reduced anti-apoptotic Bcl2 expression. Gene expression analysis revealed downregulation of cell cycle and DNA repair pathways, highlighting RCC1's critical role in sustaining oncogenic mechanisms. These findings underscore RCC1 as a gatekeeper of tumor survival, capable of resisting apoptosis and promoting metastasis. Targeting RCC1 offers a dual advantage: disrupting cancer growth and enhancing apoptotic pathways, creating an exciting opportunity for precision therapies. By illuminating RCC1's integration into survival networks, this study not only advances our understanding of cancer biology but also lays the groundwork for innovative treatments aimed at halting cancer progression and metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.